Week of Oct 26

This week: DeLLphi-305: tarlatamab added to durvalumab maintenance nearly doubles overall survival in extensive-stage SCLC, and the fight shifts to access and sequencing; FLAURA2 ctDNA analysis and PACE-LUNG: early EGFR clearance is prognostic, not predictive, so it cannot be used to skip chemotherapy; PERSEE: adding chemotherapy to pembrolizumab in PD-L1 ≥50% NSCLC more than doubles PFS, and reopens whether pembrolizumab monotherapy is a fair control arm; SAFFRON makes osimertinib plus savolitinib a chemotherapy-free standard after osimertinib progression in MET-overexpressed/amplified EGFR-mutant NSCLC; Krascendo 1: divarasib beats sotorasib/adagrasib head-to-head on PFS and OS, but the absent crossover and sotorasib-heavy control arm draw fire; OptiTROP-Lung06: sac-TMT plus pembrolizumab triples PFS versus chemo-pembrolizumab in PD-L1-negative nonsquamous NSCLC. A quick note: the voices you’re hearing are AI-generated. The stories are selected and edited by Dr. Rafael Santana-Davila. For healthcare professionals; not medical advice.

Latest digest: oncdigest.com/lung/latest
Subscribe: oncdigest.com/subscribe